Skip to main content
Fig. 4 | Journal of Nanobiotechnology

Fig. 4

From: Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity

Fig. 4

In vivo antitumor activity of F68-FRRG-DOX. a–c Tumor growth of a colon (HT29) tumor-, b breast (MDA-MB231) tumor- and c pancreatic (KPC960) tumor-bearing mice during treatment with DOX, FRRG-DOX or F68-FDOX once every three days. d The percentage of Annexin V-positive tumor cells after 9 days of treatment. e Tumor tissues stained with TUNEL on day 9 after treatment. f Tumor growth of mice treated with F68-FDOX along with cathepsin B-inhibitory siRNA or alone. Significance was determined by Tukey−Kramer post-hoc test (a–d) or Student's t test (f)

Back to article page